GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Sinopharm Group Co 1099.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

17.15

-0.06%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥669.46bn

FY2016FY2025

Net income

CN¥8.33bn

FY2016FY2025

Free cash flow

CN¥14.57bn

FY2016FY2025

Shareholders' equity

CN¥97.76bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥669.46bnCN¥680.33bnCN¥694.37bnCN¥642.67bnCN¥606.47bnCN¥531.24bnCN¥494.99bnCN¥401.01bnCN¥322.45bnCN¥300.43bn
Gross profitCN¥48.50bnCN¥51.51bnCN¥56.46bnCN¥55.21bnCN¥51.27bnCN¥46.93bnCN¥43.68bnCN¥36.35bnCN¥26.06bnCN¥23.74bn
Operating incomeCN¥18.67bnCN¥18.84bnCN¥23.52bnCN¥23.98bnCN¥22.94bnCN¥20.67bnCN¥18.78bnCN¥17.92bnCN¥13.86bnCN¥12.77bn
Net incomeCN¥8.33bnCN¥8.21bnCN¥10.54bnCN¥9.92bnCN¥9.03bnCN¥8.37bnCN¥12.36bnCN¥10.95bnCN¥9.16bnCN¥5.41bn
Diluted earnings per share2.672.643.383.182.892.684.163.683.081.95

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥454.55bnCN¥457.23bnCN¥446.25bnCN¥424.58bnCN¥390.40bnCN¥362.26bnCN¥314.14bnCN¥274.42bnCN¥197.33bnCN¥183.57bn
Cash and short-term investmentsCN¥71.68bnCN¥63.22bnCN¥74.27bnCN¥64.28bnCN¥50.68bnCN¥58.45bnCN¥45.62bnCN¥46.95bnCN¥37.53bnCN¥29.77bn
Total liabilitiesCN¥298.33bnCN¥309.78bnCN¥306.21bnCN¥296.46bnCN¥274.41bnCN¥257.57bnCN¥224.58bnCN¥194.96bnCN¥137.66bnCN¥131.73bn
DebtCN¥79.69bnCN¥76.39bnCN¥73.78bnCN¥69.59bnCN¥68.37bnCN¥68.53bnCN¥55.14bnCN¥55.10bnCN¥37.24bnCN¥33.57bn
Shareholders' equityCN¥97.76bnCN¥91.82bnCN¥86.81bnCN¥79.23bnCN¥72.03bnCN¥65.60bnCN¥55.20bnCN¥49.84bnCN¥44.58bnCN¥37.03bn
Shares outstanding3,121m3,113m3,117m3,119m3,121m3,121m2,972m2,972m2,972m2,767m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥16.46bnCN¥13.44bnCN¥19.99bnCN¥24.40bnCN¥10.83bnCN¥12.98bnCN¥21.86bnCN¥4.25bnCN¥1.94bnCN¥10.78bn
Capital spending−CN¥1.88bn−CN¥2.29bn−CN¥2.72bn−CN¥2.81bn−CN¥2.63bn−CN¥2.43bn−CN¥2.97bn−CN¥3.96bn−CN¥2.21bn−CN¥1.59bn
Free cash flowCN¥14.57bnCN¥11.15bnCN¥17.27bnCN¥21.59bnCN¥8.21bnCN¥10.55bnCN¥18.89bnCN¥290.5m−CN¥264.6mCN¥9.19bn
Dividends paid−CN¥2.47bn−CN¥3.16bn−CN¥2.98bn−CN¥2.72bn−CN¥2.51bn−CN¥2.17bn−CN¥2.04bn−CN¥1.84bn−CN¥1.61bn−CN¥1.32bn

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Sept 2023Jun 2023
RevenueCN¥324.62bnCN¥336.53bnCN¥332.94bnCN¥337.29bnCN¥343.05bnCN¥344.08bnCN¥168.74bnCN¥350.29bn
Gross profitCN¥21.64bnCN¥24.82bnCN¥24.18bnCN¥25.97bnCN¥25.54bnCN¥29.38bnCN¥168.74bnCN¥27.09bn
Operating incomeCN¥9.50bnCN¥10.00bnCN¥8.31bnCN¥9.27bnCN¥9.57bnCN¥12.08bnCN¥4.74bnCN¥11.45bn
Net incomeCN¥3.91bnCN¥4.29bnCN¥4.02bnCN¥3.89bnCN¥4.31bnCN¥5.76bnCN¥2.32bnCN¥4.78bn
Diluted earnings per share1.251.381.291.251.381.850.741.53
Cash from operations—CN¥53.73bn−CN¥39.70bnCN¥61.15bn−CN¥47.71bnCN¥70.42bnCN¥4.25bn−CN¥50.43bn
Capital spending—−CN¥1.02bn−CN¥780.0m−CN¥1.67bn−CN¥1.19bn−CN¥1.44bn−CN¥576.0m−CN¥837.0m
Free cash flow—CN¥52.71bn−CN¥40.48bnCN¥59.48bn−CN¥48.90bnCN¥68.97bnCN¥3.68bn−CN¥51.27bn
Total assetsCN¥470.64bnCN¥454.55bnCN¥489.05bnCN¥457.23bnCN¥500.01bnCN¥446.25bnCN¥419.95bnCN¥486.17bn
Cash and short-term investmentsCN¥48.74bnCN¥71.68bnCN¥54.89bnCN¥63.22bnCN¥50.44bnCN¥74.27bnCN¥44.26bnCN¥40.01bn
DebtCN¥124.80bnCN¥82.59bnCN¥110.46bnCN¥88.91bnCN¥117.62bnCN¥85.88bnCN¥88.77bnCN¥110.38bn
Shareholders' equityCN¥99.14bnCN¥97.76bnCN¥93.56bnCN¥91.82bnCN¥87.93bnCN¥86.81bnCN¥115.93bnCN¥81.02bn

Financial ratios

Data as of 15 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2008FY2007FY2006
Gross margin7.2%7.6%8.1%8.6%8.5%8.8%———
Operating margin2.8%2.8%3.4%3.7%3.8%3.9%———
Net margin1.2%1.2%1.5%1.5%1.5%1.6%———
Return on equity8.5%8.9%12.1%12.5%12.5%12.8%———
Return on assets1.8%1.8%2.4%2.3%2.3%2.3%———
Free cash flow yield33.5%28.8%41.5%49.7%24.6%28.1%———
Revenue growth-1.6%-2.0%8.0%6.0%14.2%7.3%———
Earnings growth1.5%-22.1%6.2%9.9%7.9%-32.3%———
Current ratio1.41x1.39x1.39x1.36x1.33x1.31x———
Debt to equity0.82x0.93x0.94x0.98x1.05x1.13x———
Equity ratio21.5%20.1%19.5%18.7%18.5%18.1%———
Interest coverage6.97x5.92x6.84x5.85x5.25x5.19x———
R&D as a share of sales——————0.1%0.1%0.1%
Buybacks as a share of market value-0.2%0.1%0.1%0.1%0.0%-5.0%———

Growth per year

Compound annual rate

3 years5 years10 years
Revenue1.4%4.7%9.7%
Operating income-8.0%-2.0%5.7%
Net income-5.7%-0.1%6.6%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin7.4%7.9%8.1%8.2%
Operating margin2.8%3.2%3.4%3.6%
Net margin1.2%1.4%1.4%1.7%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings6.57.65.55.64.85.96.17.89.214.6
Price to sales0.10.10.10.10.10.10.10.20.30.3

Dividends and splits

Per share, in the currency the company pays

Paid for 16 years. Last went ex-dividend on 23 Jun 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year0.6840.7390.9560.900.8720.8390.6520.671

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.